These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 23837586

  • 1. Prostaglandin E1 -containing nanoparticles improve walking activity in an experimental rat model of intermittent claudication.
    Ishihara T, Yamashita Y, Takasaki N, Yamamoto S, Hayashi E, Tahara K, Takenaga M, Yamakawa N, Ishihara T, Kasahara T, Mizushima T.
    J Pharm Pharmacol; 2013 Aug; 65(8):1187-94. PubMed ID: 23837586
    [Abstract] [Full Text] [Related]

  • 2. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1).
    Scheffler P, Gross J, Markwirth T, Maier J, Schieffer H.
    Eur J Clin Pharmacol; 1996 Aug; 51(3-4):235-9. PubMed ID: 9010691
    [Abstract] [Full Text] [Related]

  • 3. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
    Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC.
    J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
    [Abstract] [Full Text] [Related]

  • 4. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
    Belcaro G, Laurora G, Nicolaides AN, Agus G, Cesarone MR, DeSanctis MT, Incandela L, Ricci A, Cazaubon M, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Iacobitti P, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Bucci M, Ferrari PG, Corsi M, Pomante P, Mezzanotte L, Geroulakos G.
    Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
    [Abstract] [Full Text] [Related]

  • 5. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA, Malatino LS, Santonocito M, Messina R, Attinà T, Dell'Arte S, Sarnataro F.
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
    [Abstract] [Full Text] [Related]

  • 6. Effects of intravenous lipoprostaglandin E1 on neurogenic intermittent claudication.
    Murakami M, Takahashi K, Sekikawa T, Yasuhara K, Yamagata M, Moriya H.
    J Spinal Disord; 1997 Dec; 10(6):499-504. PubMed ID: 9438815
    [Abstract] [Full Text] [Related]

  • 7. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
    Mangiafico RA, Messina R, Attinà T, Dell'Arte S, Giuliano L, Malatino LS.
    Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
    [Abstract] [Full Text] [Related]

  • 8. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
    Laurora G, Corsi M, Bucci M, Cesarone MR, Belcaro G, Dugall M.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
    [Abstract] [Full Text] [Related]

  • 9. Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release.
    Takenaga M, Ishihara T, Ohta Y, Tokura Y, Hamaguchi A, Igarashi R, Mizushima T.
    J Control Release; 2010 Dec 01; 148(2):249-54. PubMed ID: 20709122
    [Abstract] [Full Text] [Related]

  • 10. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
    Belcaro G, Nicolaides AN, Agus G, Cesarone MR, Geroulakos G, Pellegrini L, De Sanctis MT, Incandela L, Ricci A, Mondani P, De Angelis R, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Dugall M, Bucci M, Martines G, Ferrari PG, Corsi M, Di Francescantonio D.
    Angiology; 2000 Aug 01; 51(8 Pt 2):S15-26. PubMed ID: 10959507
    [Abstract] [Full Text] [Related]

  • 11. Vasodilating effect and tissue accumulation of prostaglandin E1 incorporated in lipid microspheres on the rat ductus arteriosus.
    Chino Y, Minagawa T, Kohno Y, Fukushima K, Momma K.
    Jpn J Pharmacol; 1999 Sep 01; 81(1):107-14. PubMed ID: 10580378
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial.
    Diehm C, Balzer K, Bisler H, Bulling B, Camci M, Creutzig A, Gruss JD, Horsch S, Odemar F, Piehler U, Rogatti W, Scheffler P, Spengel F, Treese N, Turowski A, Waldhausen P, Weber B, Weiss T.
    J Vasc Surg; 1997 Mar 01; 25(3):537-44. PubMed ID: 9081136
    [Abstract] [Full Text] [Related]

  • 13. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
    Weiss T, Eckstein H, Weiss C, Diehm C.
    Vasc Med; 1998 Mar 01; 3(3):171-5. PubMed ID: 9892509
    [Abstract] [Full Text] [Related]

  • 14. Midterm results of prostaglandin E1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication.
    Nakanishi K, Tanaka M, Misawa H, Takigawa T, Ozaki T.
    Spine (Phila Pa 1976); 2008 Jun 01; 33(13):1465-9. PubMed ID: 18520942
    [Abstract] [Full Text] [Related]

  • 15. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S, Mizushima Y, Aihara H, Yokoyama K, Watanabe M, Yanagawa A.
    Drugs Exp Clin Res; 1985 Jun 01; 11(9):627-31. PubMed ID: 3880049
    [Abstract] [Full Text] [Related]

  • 16. [Rehabilitation program in patients with moderate-to-severe intermittent claudication: immediate results and one year follow-up].
    Rossini D, Bulckaen M, Di Marco S, Giovannetti R, Giuntoli F, Lacopetti L, Vergoni W.
    Monaldi Arch Chest Dis; 2007 Jun 01; 68(2):110-4. PubMed ID: 17886772
    [Abstract] [Full Text] [Related]

  • 17. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis.
    Amendt K.
    Angiology; 2005 Jun 01; 56(4):409-15. PubMed ID: 16079924
    [Abstract] [Full Text] [Related]

  • 18. Improvement of microcirculation after percutaneous transluminal angioplasty in the lower limb with prostaglandin E1.
    Heider P, Wildgruber M, Wolf O, Schuster T, Lutzenberger W, Berger H, Eckstein HH.
    Prostaglandins Other Lipid Mediat; 2009 Jan 01; 88(1-2):23-30. PubMed ID: 18832042
    [Abstract] [Full Text] [Related]

  • 19. Ocular and orbital blood flow velocity in patients with peripheral vascular disease and diabetes treated with intravenous prostaglandin E1.
    Steigerwalt RD, Belcaro GV, Christopoulos V, Incandela L, Cesarone MR, De Sanctis MT.
    J Ocul Pharmacol Ther; 2001 Dec 01; 17(6):529-35. PubMed ID: 11777176
    [Abstract] [Full Text] [Related]

  • 20. Improvement of peripheral and cardiopulmonary performance after a short-term exercise program with additive prostaglandin E1.
    Cachovan M, Rogatti W.
    Angiology; 2001 Jun 01; 52(6):381-91. PubMed ID: 11437028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.